Opus Genetics (IRD) Total Non-Current Liabilities (2010 - 2026)

Opus Genetics (IRD) has reported Total Non-Current Liabilities for 17 consecutive years, with $10.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 56.55% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (down 56.55% YoY), while the FY2025 annual figure was $8.9 million, down 21.12% from the prior year.
• Total Non-Current Liabilities climbed to $10.5 million in Q1 2026 per IRD's latest filing, from $8.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $30.2 million in Q3 2025 and bottomed at $2.7 million in Q3 2022.
• Historically, Total Non-Current Liabilities has averaged $8.9 million across 5 years, with a median of $5.7 million in 2023.
• Annual changes were most pronounced in 2025 — Total Non-Current Liabilities jumped 404.81% — and 2026, when it sank 56.55%.
• Opus Genetics' Total Non-Current Liabilities stood at $2.8 million in 2022, then surged by 45.91% to $4.0 million in 2023, then surged by 181.18% to $11.3 million in 2024, then dropped by 21.12% to $8.9 million in 2025, then rose by 18.27% to $10.5 million in 2026.
• Business Quant data shows IRD's Total Non-Current Liabilities at $10.5 million in Q1 2026, $8.9 million in Q4 2025, and $30.2 million in Q3 2025.